FDA official challenges safety, efficacy of Aurinia lupus med in now-deleted LinkedIn post targeting surrogate endpoints
30th September 2025 Uncategorised 0A now-deleted LinkedIn post from a top FDA official has raised the hackles of Aurinia Pharmaceuticals as industry watchers puzzle over the official’s decision to target the approvability of surrogate endpoints—and single out Aurinia’s lupus nephritis med Lupkynis—via social media.
More: FDA official challenges safety, efficacy of Aurinia lupus med in now-deleted LinkedIn post targeting surrogate endpoints
Source: fierce